BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis (Q39213203)

10 September 2017

0 references

BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis (English)

1 reference

10 September 2017

0 references

1 reference

1 reference

metastatic colon cancer

1 reference

1 reference

1 reference

Chen Mao

1

1 reference

10 September 2017

Ru-Yan Liao

2

1 reference

10 September 2017

Li-Xin Qiu

3

1 reference

10 September 2017

Xi-Wen Wang

4

1 reference

10 September 2017

Hong Ding

5

1 reference

10 September 2017

Qing Chen

6

1 reference

10 September 2017

21 September 2010

1 reference

Molecular Biology Reports

10 September 2017

1 reference

10 September 2017

38

1 reference

10 September 2017

4

1 reference

10 September 2017

2219-2223

1 reference

https://scigraph.springernature.com/pub.10.1007/s11033-010-0351-4

10 September 2017

0 references

cites work

Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Systemic therapy for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Ligand-induced, receptor-mediated dimerization and activation of EGF receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11033-010-0351-4

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Statistical aspects of the analysis of data from retrospective studies of disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

BRAFMutation in Metastatic Colorectal Cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20857202

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11033-010-0351-4

1 reference

10 September 2017

1 reference